ValuEngine lowered shares of Spark Therapeutics (NASDAQ:ONCE) from a buy rating to a hold rating in a research report released on Tuesday morning, ValuEngine reports.

ONCE has been the topic of several other reports. Zacks Investment Research downgraded shares of Spark Therapeutics from a hold rating to a sell rating in a research report on Wednesday, August 14th. Mizuho restated a hold rating and set a $114.50 price target on shares of Spark Therapeutics in a report on Monday, August 12th. Thirteen equities research analysts have rated the stock with a hold rating, The stock presently has an average rating of Hold and an average price target of $106.00.

ONCE stock opened at $110.89 on Tuesday. The company has a current ratio of 4.67, a quick ratio of 4.35 and a debt-to-equity ratio of 0.35. Spark Therapeutics has a one year low of $34.53 and a one year high of $114.20. The firm has a market capitalization of $4.28 billion, a PE ratio of -52.55 and a beta of 2.05. The firm has a 50-day moving average of $108.41 and a two-hundred day moving average of $103.27.

A number of large investors have recently bought and sold shares of ONCE. Paulson & CO. Inc. purchased a new stake in Spark Therapeutics in the 2nd quarter worth about $77,584,000. Boxer Capital LLC acquired a new position in Spark Therapeutics in the 2nd quarter valued at approximately $61,428,000. TIG Advisors LLC purchased a new stake in Spark Therapeutics in the 2nd quarter worth approximately $61,301,000. Renaissance Technologies LLC purchased a new stake in Spark Therapeutics in the 2nd quarter worth approximately $39,897,000. Finally, Perceptive Advisors LLC purchased a new stake in Spark Therapeutics in the 2nd quarter worth approximately $35,833,000. 88.36% of the stock is currently owned by hedge funds and other institutional investors.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

Further Reading: What is Depreciation?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.